Holen Sie sich die Stockscreener-App
35.52
0.91%
0.32
Handel nachbörslich:
35.52
Schlusskurs vom Vortag:
$35.20
Offen:
$35.44
24-Stunden-Volumen:
309.71K
Relative Volume:
0.72
Marktkapitalisierung:
$1.15B
Einnahmen:
$796.33M
Nettoeinkommen (Verlust:
$74.95M
KGV:
17.39
EPS:
2.0427
Netto-Cashflow:
$329.83M
1W Leistung:
-0.06%
1M Leistung:
-2.92%
6M Leistung:
-21.62%
1J Leistung:
+11.77%
1-Tages-Spanne:
$35.26
$36.03
1-Wochen-Bereich:
$34.00
$36.51
52-Wochen-Spanne:
$29.19
$50.79
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Firmenname
Collegium Pharmaceutical Inc
Sektor
Telefon
781-713-3699
Adresse
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
35.52 | 1.14B | 796.33M | 74.95M | 329.83M | 2.0427 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-01-10 | Hochstufung | Needham | Hold → Buy |
| 2024-07-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-05-10 | Herabstufung | Needham | Buy → Hold |
| 2024-05-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-08-25 | Bestätigt | Needham | Buy |
| 2023-05-02 | Fortgesetzt | Jefferies | Buy |
| 2022-08-08 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-02-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-14 | Eingeleitet | BWS Financial | Sell |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-19 | Fortgesetzt | Jefferies | Buy |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-03 | Fortgesetzt | H.C. Wainwright | Buy |
| 2019-04-12 | Fortgesetzt | Janney | Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-01-16 | Bestätigt | Needham | Buy |
| 2018-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2018-02-07 | Bestätigt | Needham | Buy |
| 2017-12-05 | Bestätigt | Needham | Buy |
| 2017-09-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-09-13 | Eingeleitet | Gabelli & Co | Buy |
| 2015-06-01 | Eingeleitet | Jefferies | Buy |
| 2015-06-01 | Eingeleitet | Needham | Buy |
| 2015-06-01 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Collegium Pharmaceutical Inc Aktie (COLL) Neueste Nachrichten
Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance
Collegium Pharmaceutical Inc (COLL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Collegium Pharmaceutical Inc (COLL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Collegium Pharmaceutical, Inc. Revenue Breakdown – FWB:354 - TradingView
Collegium Pharmaceutical Inc (COLL) Institutional Confidence - TradingKey
Collegium Pharmaceutical, Inc. Revenue Breakdown – BOATS:COLL - TradingView
Collegium Pharmaceutical Inc (COLL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Collegium Pharmaceutical stock gains 2.46% as CollegiumPharma schedules Q2 results call for August 6 - Traders Union
Collegium's Aug. 6 results will be followed by an 8 a.m. webcast - Stock Titan
Is Collegium Pharmaceutical Inc (COLL) a Bargain After 3.1% Drop? GF Value Says Undervalued - GuruFocus
Collegium Pharmaceutical Inc. (COLL) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Pharma Company Moving Headquarters From Suburbs To Downtown Boston - Bisnow
Collegium Pharmaceutical to relocate headquarters to Boston - Investing.com
DivcoWest Welcomes Collegium Pharmaceutical to One Lincoln - Business Wire
Collegium Pharmaceutical to relocate headquarters to Boston By Investing.com - Investing.com Canada
After More Than 20 Years, Collegium Plans Boston Headquarters Move - Stock Titan
Collegium Pharmaceutical Inc. (COLL) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston - Sahm
Is Collegium Pharmaceutical (COLL) Still Undervalued As Its Growth Narrative Holds Up? - Yahoo Finance Singapore
Collegium Pharmaceutical Q1 2026 Earnings: EPS Surpasses Estimates by 8.43%Special Dividend Alert - dars.gov.et
COLL5756983 Bond Coupon Profile — Rate & Payments - TradingView
Collegium Pharmaceutical (COLL) Stock Looks Fairly Valued With Strong Returns But Mixed Earnings## - simplywall.st
Form 144 COLLEGIUM PHARMACEUTICAL For: 17 July By Investing.com - Investing.com Nigeria
(COLL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Planned sale of 13,920 COLL shares follows earlier 8,095-share disposal (COLL) - Stock Titan
enGene names Michael Heffernan board chairman as Richard Glickman steps down - Bitget
ETFs Investing in Collegium Pharmaceutical, Inc. Stocks - TradingView
COLL5756983 Bond Risk Profile - TradingView
COLL5756983 Bond Profile — Key Metrics - TradingView
US19459JAC8 Bond Coupon Profile — Rate & Payments - TradingView
US19459JAC8 Bond Risk Profile - TradingView
[144] COLLEGIUM PHARMACEUTICAL, INC SEC Filing - Stock Titan
Enterprise value to EBITDA forward of Collegium Pharmaceutical, Inc. – NASDAQ:COLL - TradingView
Collegium Pharmaceutical (COLL) Draws Fresh Valuation Attention, Is It Still A Bargain? - simplywall.st
4 defensive stocks to take refuge in as tech sell-off continues - MSN
Collegium Pharmaceutical stock gains 12% in three months: Here's why - MSN
Price to earnings forward of Collegium Pharmaceutical, Inc. – NASDAQ:COLL - TradingView
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? - Yahoo Finance
Price to book forward of Collegium Pharmaceutical, Inc. – NASDAQ:COLL - TradingView
New Strong Buy Stocks for July 6th - Yahoo Finance Singapore
Collegium Pharmaceutical Q1 2026 slides: ADHD growth drives earnings beat - Investing.com
Price to earnings forward of Collegium Pharmaceutical, Inc. – FWB:354 - TradingView
Enterprise value to EBITDA forward of Collegium Pharmaceutical, Inc. – FWB:354 - TradingView
Price to sales forward of Collegium Pharmaceutical, Inc. – FWB:354 - TradingView
COLLCollegium Pharmaceutical Inc Website Traffic and Mobile Apps Usage - Finviz
Is Collegium Pharmaceutical (COLL) A Bargain On Its Azstarys Deal And 2026 Guidance? - simplywall.st
Collegium Pharmaceutical (COLL) Gains 3.2% as Stock Approaches Key ResistanceTurnaround Stocks - dars.gov.et
2 Profitable Stocks to Keep an Eye On and 1 We Brush Off - Yahoo Finance
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why - The Globe and Mail
Barclays Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Collegium (NASDAQ: COLL) details $655.6M AZSTARYS acquisition terms - Stock Titan
Finanzdaten der Collegium Pharmaceutical Inc-Aktie (COLL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
2.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):